Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 9.16M | P/E | - | EPS this Y | 65.30% | Ern Qtrly Grth | - |
| Income | -43.3M | Forward P/E | -1.07 | EPS next Y | 72.00% | 50D Avg Chg | -40.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -73.00% |
| Dividend | N/A | Price/Book | 2.14 | EPS next 5Y | - | 52W High Chg | -94.00% |
| Recommedations | 3.00 | Quick Ratio | 0.63 | Shares Outstanding | 122.08M | 52W Low Chg | 390.00% |
| Insider Own | 1.02% | ROA | -106.64% | Shares Float | 120.96M | Beta | 1.15 |
| Inst Own | 7.42% | ROE | -541.02% | Shares Shorted/Prior | 10.34M/8.59M | Price | 0.08 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 31,696,143 | Target Price | 4.00 |
| Oper. Margin | - | Earnings Date | Nov 8 | Volume | 261,996,261 | Change | 0.00% |
About Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.